Pharmaceuticals

Evolus

Evolus released FY2026 Q1 earnings on May 4 After-Market EST, actual revenue USD 73.14 M (forecast USD 72.17 M), actual EPS USD -0.1637 (forecast USD -0.22)

Evolus to Release FY2026 Q1 Earnings on May 4 After-Market EST, Forecast Revenue USD 72.17 M, EPS USD -0.22

Evolus released FY2025 Q4 earnings on March 3 After-Market EST with actual revenue USD 0 (forecast USD 89.58 M) and actual EPS USD 0 (forecast USD -0.0475)

Evolus released FY2025 earnings on March 3 After-Market EST, actual revenue USD 297.18 M (forecast USD 296.47 M), actual EPS USD -0.801 (forecast USD -0.87)

Evolus to Release FY2025 Q4 Earnings on March 3 After-Market EST, Forecast Revenue USD 89.58 M, EPS USD -0.0475

Stifel Nicolaus analyst maintains buy rating on Evolus

Mizuho analyst reiterates buy rating on Evolus

Evolus released FY2025 Q3 earnings on November 5 After-Market EST, actual revenue USD 68.97 M (forecast USD 67.42 M), actual EPS USD -0.2431 (forecast USD -0.2675)

Evolus released FY2025 9 Months earnings on November 5 After-Market (EST), actual revenue USD 206.88 M, actual EPS USD -0.8053

Evolus to Release FY2025 Q3 Earnings on November 5 After-Market EST, Forecast Revenue USD 67.42 M, EPS USD -0.2675

Goodman covers healthcare industry and focuses on specific stocks

Evolus Inc announces positive results for Evolysse Sculpt study

Evolus Inc. Releases Scientific Investor Presentation Showcasing Aesthetic Treatment Advances

Evolus released FY2025 Semi-Annual Earnings on August 5 After-Market EST, with actual revenue of USD 137.91 M and EPS of USD -0.5619

Evolus released FY2025 Q2 earnings on August 5 After-Market (EST), actual revenue USD 69.39 M (forecast USD 82.04 M), actual EPS USD -0.2656 (forecast USD -0.2)

Evolus to release FY2025 Q2 earnings report on August 5 After-Market EST, forecast revenue USD 82.04 M, EPS USD -0.2

Evolus Grants RSUs to Six New Non-Executive Employees

Evolus Inc. collaborates with Symatese to promote Nuceiva® in France

Evolus Price Drops Following Insider Sale

Evolus Inc. Announces New Employee Incentive Program

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Silexion Therapeutics

Micware

GCL Global

MetaVia

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Bristol-Myers Squibb Company

EOLS

A global beauty company, Evolus, Inc. (NASDAQ: EOLS), based in Newport Beach, California, revealed its plan to launch Estyme® in Europe on May 16th. Estyme® comprises four injectable hyaluronic acid (HA) gels, expanding the company's presence in the international dermal filler market. Designed to offer a broad spectrum of aesthetic solutions, this collection signifies Evolus's venture into diversifying its product portfolio.

Unusual Whales

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

SBIO

IBBQ

LABU

Evolus (EOLS) reported Q4 2025 revenue of US$90.3 million and a basic EPS of approximately US$0.00, with a net income of US$0.13 million. Despite trailing losses of US$51.6 million over the past year, the company shows signs of improving margins and forecasts 73.62% yearly earnings growth. However, concerns remain about the sustainability of profitability amid a challenging aesthetics market. The stock trades at a low P/S of 1.4x compared to peers, indicating potential for growth but also skepticism about future earnings durability.

Simplywall

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Evolus (EOLS) Breakeven Q4 EPS Tests Skeptics Of Its Profitability Path

Evolus shares are trading higher after the company reported better-than-expected Q1 sales results.

benzinga_article

Analyst Douglas Tsao of H.C. Wainwright has maintained a Buy rating on Evolus, reaffirming a price target of $13.00. This decision is based on Evolus' strong first-quarter performance, positive adjusted EBITDA, and guidance for double-digit revenue growth. Tsao highlights the company's effective commercial strategy and stable market share, indicating resilience amid macro pressures. Mizuho Securities also reiterated a Buy rating with a $15.00 price target.

Tip Ranks

Mizuho Financial Group, Inc.

Mizuho Financial

Evolus Maintains Buy Rating as Scalable Growth Story Solidifies; $13 Price Target Reaffirmed

Evolus, Inc. reported Q1 earnings with a 7% year-over-year revenue increase to $73.1 million, driven by its neurotoxin Jeuveau. The company achieved positive adjusted EBITDA of $0.6 million, marking a significant improvement from a loss last year. Gross margins remained strong at 67%. Evolus is expanding its customer base, with nearly 500 new accounts in Q1 and a growing rewards program. However, it faces challenges from a new 15% tariff in South Korea and competitive pressures in the aesthetic market. Management remains optimistic about future growth and profitability by 2026.

Evolus Earnings Call Highlights Profitable Growth Path

Evolus, Inc. reported a 6.7% year-over-year revenue increase to $73.14M for Q1 2026, with a narrowed net loss of $10.67M and diluted EPS of ($0.16). The revenue growth was attributed to the Evolysse® launch and international expansion of Jeuveau®. The company is focusing on the cash-pay aesthetic channel and plans to launch the full Evolysse® line in Europe in Q2 2026. Additionally, a $30M revolving credit facility was opened in March 2026 to support operations.

TradingView

Evolus, Inc. 1Q 2026: Revenue $73.14M, EPS ($0.16) — 10-Q Summary

Earnings Watch

Evolus | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 73.14 M

Evolus(EOLS.US)